TITLE:
An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer

CONDITION:
Colonic Neoplasms

INTERVENTION:
EP2101

SUMMARY:

      EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is
      designed to activate the immune system to develop a response against tumor cells in order to
      delay or prevent the recurrence of cancer. This study will test the safety and measure the
      level of immune stimulating capability of EP2101 in patients with Colon Cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of Colon Cancer, stage III

          -  At least four weeks following prior standard treatment, with no evidence of disease

          -  Must use adequate birth control

        Exclusion Criteria:

          -  Prior cancer vaccine therapy or concurrent participation in any other investigational
             study

          -  A history of HIV, Hepatitis B or C, or any other acute medical condition which may
             compromise patient safety or the activity of the study vaccine treatment

          -  A history of adverse reactions following administration of any vaccines, or a history
             of hypersensitivity to any components of the study vaccine

          -  Women who are pregnant, intend to become pregnant, or who are breast feeding
      
